The Experts below are selected from a list of 7107 Experts worldwide ranked by ideXlab platform
Ayhan Songar - One of the best experts on this subject based on the ideXlab platform.
-
The effects of oxiracetam (ISF 2522) in patients with organic brain syndrome (a double‐blind controlled study with piracetam)
Drug Development Research, 2005Co-Authors: Turan M. Itil, Gopi N. Menon, M. Mahir Bozak, Ayhan SongarAbstract:Itil, T.M., G.N. Menon, M. Bozak, and A. Songar: The effects of oxiracetam, (ISF 2522) in patients with organic brain syndrome (a double-blind controlled study with piracetam). Drug Dev. Res. 2:447–461, 1982. In a double-blind controlled trial, the clinical effects of oxiracetam, a new “Nootropic” compound, were investigated in a group of 60 elderly patients with organic mental disorders (DSM-III). The starting dose of both oxiracetam and the control drug, piracetam, was 400 mg. The dosage was increased by 400 mg at weekly intervals up to 2,400 mg daily (sixth week). During the following 6 weeks the administered dose was fixed at 2,400 mg daily. Most of the important target symptoms improved significantly over time, both subjectively (i.e., rating scales) and objectively (i.e., psychological tests), after administration of either oxiracetam or piracetam. In comparison to piracetam, oxiracetam exhibited more statistically significant improvement in the memory factor, whereas piracetam showed more improvement than oxiracetam in factors of paranoid ideation and agitation. Both drugs were tolerable and did not elicit any significant side effects. It was postulated that “Nootropics” may represent a new group of CNS effective compounds, and thus be a “second generation” of psychotropics, which have more direct effects on the central target organs than are presently found in the “classical” psychotropics.
Turan M. Itil - One of the best experts on this subject based on the ideXlab platform.
-
The effects of oxiracetam (ISF 2522) in patients with organic brain syndrome (a double‐blind controlled study with piracetam)
Drug Development Research, 2005Co-Authors: Turan M. Itil, Gopi N. Menon, M. Mahir Bozak, Ayhan SongarAbstract:Itil, T.M., G.N. Menon, M. Bozak, and A. Songar: The effects of oxiracetam, (ISF 2522) in patients with organic brain syndrome (a double-blind controlled study with piracetam). Drug Dev. Res. 2:447–461, 1982. In a double-blind controlled trial, the clinical effects of oxiracetam, a new “Nootropic” compound, were investigated in a group of 60 elderly patients with organic mental disorders (DSM-III). The starting dose of both oxiracetam and the control drug, piracetam, was 400 mg. The dosage was increased by 400 mg at weekly intervals up to 2,400 mg daily (sixth week). During the following 6 weeks the administered dose was fixed at 2,400 mg daily. Most of the important target symptoms improved significantly over time, both subjectively (i.e., rating scales) and objectively (i.e., psychological tests), after administration of either oxiracetam or piracetam. In comparison to piracetam, oxiracetam exhibited more statistically significant improvement in the memory factor, whereas piracetam showed more improvement than oxiracetam in factors of paranoid ideation and agitation. Both drugs were tolerable and did not elicit any significant side effects. It was postulated that “Nootropics” may represent a new group of CNS effective compounds, and thus be a “second generation” of psychotropics, which have more direct effects on the central target organs than are presently found in the “classical” psychotropics.
Elisabetta Teodori - One of the best experts on this subject based on the ideXlab platform.
-
molecular simplification of 1 4 diazabicyclo 4 3 0 nonan 9 ones gives piperazine derivatives that maintain high Nootropic activity
Journal of Medicinal Chemistry, 2000Co-Authors: Dina Manetti, Carla Ghelardini, Alessandro Bartolini, Silvia Dei, Nicoletta Galeotti, Fulvio Gualtieri, Maria Novella Romanelli, Elisabetta TeodoriAbstract:Several 4-substituted 1-acylpiperazines, obtained by molecular simplification of 4-substituted 1,4-diazabicyclo[4.3.0]nonan-9-ones, have been synthesized and tested in vivo on the mouse passive avoidance test, to evaluate their Nootropic activity. The results show that, apparently, an N-acylpiperazine group can mimic the 2-pyrrolidinone ring of 1,4-diazabicyclo[4.3.0]nonan-9-one, as the compounds of the new series maintain high Nootropic activity. Moreover molecular simplification produces more clear-cut structure−activity relationships with respect to the parent series. The mechanism of action also appears to be similar in the two series. In fact, although the molecular mechanism remains to be elucidated, the most potent compound of each class (DM232 and 13, DM235) is able to increase acetylcholine release in rat brain. Piperazine derivatives represent a new class of Nootropic drugs with an in vivo pharmacological profile very similar to that of piracetam, showing much higher potency with respect to the ...
-
design synthesis and preliminary pharmacological evaluation of 1 4 diazabicyclo 4 3 0 nonan 9 ones as a new class of highly potent Nootropic agents
Journal of Medicinal Chemistry, 2000Co-Authors: Dina Manetti, Carla Ghelardini, Alessandro Bartolini, Cristina Bellucci, Silvia Dei, Nicoletta Galeotti, Fulvio Gualtieri, Maria Novella Romanelli, Serena Scapecchi, Elisabetta TeodoriAbstract:Several 4-substituted 1,4-diazabicyclo[4.3.0]nonan-9-ones have been synthesized and tested in vivo on mouse passive avoidance test, to evaluate their Nootropic activity. The results show that they represent a new class of Nootropic drugs with a pharmacological profile very similar to that of piracetam, showing much higher potency with respect to the reference. Among the compounds studied, 7 (DM 232) shows outstanding potency, being active at the dose of 0. 001 mg kg(-1) sc.
Gopi N. Menon - One of the best experts on this subject based on the ideXlab platform.
-
The effects of oxiracetam (ISF 2522) in patients with organic brain syndrome (a double‐blind controlled study with piracetam)
Drug Development Research, 2005Co-Authors: Turan M. Itil, Gopi N. Menon, M. Mahir Bozak, Ayhan SongarAbstract:Itil, T.M., G.N. Menon, M. Bozak, and A. Songar: The effects of oxiracetam, (ISF 2522) in patients with organic brain syndrome (a double-blind controlled study with piracetam). Drug Dev. Res. 2:447–461, 1982. In a double-blind controlled trial, the clinical effects of oxiracetam, a new “Nootropic” compound, were investigated in a group of 60 elderly patients with organic mental disorders (DSM-III). The starting dose of both oxiracetam and the control drug, piracetam, was 400 mg. The dosage was increased by 400 mg at weekly intervals up to 2,400 mg daily (sixth week). During the following 6 weeks the administered dose was fixed at 2,400 mg daily. Most of the important target symptoms improved significantly over time, both subjectively (i.e., rating scales) and objectively (i.e., psychological tests), after administration of either oxiracetam or piracetam. In comparison to piracetam, oxiracetam exhibited more statistically significant improvement in the memory factor, whereas piracetam showed more improvement than oxiracetam in factors of paranoid ideation and agitation. Both drugs were tolerable and did not elicit any significant side effects. It was postulated that “Nootropics” may represent a new group of CNS effective compounds, and thus be a “second generation” of psychotropics, which have more direct effects on the central target organs than are presently found in the “classical” psychotropics.
M. Mahir Bozak - One of the best experts on this subject based on the ideXlab platform.
-
The effects of oxiracetam (ISF 2522) in patients with organic brain syndrome (a double‐blind controlled study with piracetam)
Drug Development Research, 2005Co-Authors: Turan M. Itil, Gopi N. Menon, M. Mahir Bozak, Ayhan SongarAbstract:Itil, T.M., G.N. Menon, M. Bozak, and A. Songar: The effects of oxiracetam, (ISF 2522) in patients with organic brain syndrome (a double-blind controlled study with piracetam). Drug Dev. Res. 2:447–461, 1982. In a double-blind controlled trial, the clinical effects of oxiracetam, a new “Nootropic” compound, were investigated in a group of 60 elderly patients with organic mental disorders (DSM-III). The starting dose of both oxiracetam and the control drug, piracetam, was 400 mg. The dosage was increased by 400 mg at weekly intervals up to 2,400 mg daily (sixth week). During the following 6 weeks the administered dose was fixed at 2,400 mg daily. Most of the important target symptoms improved significantly over time, both subjectively (i.e., rating scales) and objectively (i.e., psychological tests), after administration of either oxiracetam or piracetam. In comparison to piracetam, oxiracetam exhibited more statistically significant improvement in the memory factor, whereas piracetam showed more improvement than oxiracetam in factors of paranoid ideation and agitation. Both drugs were tolerable and did not elicit any significant side effects. It was postulated that “Nootropics” may represent a new group of CNS effective compounds, and thus be a “second generation” of psychotropics, which have more direct effects on the central target organs than are presently found in the “classical” psychotropics.
